{"id":456725,"date":"2021-03-12T08:03:29","date_gmt":"2021-03-12T13:03:29","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=456725"},"modified":"2021-03-12T08:03:29","modified_gmt":"2021-03-12T13:03:29","slug":"cymabay-therapeutics-to-report-fourth-quarter-and-full-year-2020-financial-results-on-thursday-march-25-2021","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cymabay-therapeutics-to-report-fourth-quarter-and-full-year-2020-financial-results-on-thursday-march-25-2021\/","title":{"rendered":"CymaBay Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results on Thursday, March 25, 2021"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">NEWARK, Calif., March  12, 2021  (GLOBE NEWSWIRE) &#8212; CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio webcast on Thursday, March 25, 2021 at 4:30 p.m. Eastern Time to discuss financial results for the fourth quarter and year ended December 31, 2020 and to provide a business update.<\/p>\n<p align=\"justify\">\n        <strong>Conference Call Details<\/strong><br \/>\n        <br \/>To access the live conference call, please dial 877-407-0784 from the U.S. and Canada, or 201-689-8560 internationally, Conference ID# 13715944. To access the live and subsequently archived webcast of the conference call, go to the Investors section of the company&#8217;s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=m7DPEG3INxtbYYcAo8eiXzdHcszdHeNRn5tzJtUSRqleEheUzoQDjrMEfS4YnfTA4AkG8jWje0kpIiyZ_yYQtuHv4wVVSQKCow3KEA5QGyQ=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">http:\/\/ir.cymabay.com\/events<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>About CymaBay <\/strong><br \/>\n        <br \/>CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need. CymaBay is developing seladelpar, a potent, selective, orally active PPAR\u03b4 agonist for patients with primary biliary cholangitis (PBC). Seladelpar has received an orphan designation from the US Food and Drug administration (FDA) and the European Medicine Agency (EMA). Seladelpar also received Breakthrough Therapy Designation from the FDA for early stage PBC and PRIority MEdicines status from the EMA. CymaBay is currently commencing a global, Phase 3 registration study of seladelpar for PBC. This study is a 52-week, placebo-controlled, randomized, phase 3 study to evaluate the safety and efficacy of seladelpar (RESPONSE) in patients with PBC. For more information about RESPONSE, please visit: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Ojf95hSvJRaAIA-_zm1G8mYRyeluy5V4wGSvSWnb85jQoUJloggOmxkiqbWD2No_oXiX6TQmqC6AafbQ8Np8rOuIHKjPMg7zwdG8ONUreZk=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.pbcstudies.com<\/a>.<\/p>\n<p align=\"justify\">For additional information about CymaBay visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=qon_QZm8L8MyyKxUnQduRNNwJ9xGELiuLnkeshgrXsHvBsE0Fq0Imhx9cMu6HlO6LS8D-ky-FefYaRt3sOIJvQ==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.cymabay.com<\/a>.<\/p>\n<p>\n        <strong>Public Relations Contact<\/strong><br \/>\n        <strong>:<\/strong>\n      <\/p>\n<p>Glenn Silver<br \/>Lazar-FINN Partners<br \/>(973) 818-8198<br \/>Glenn.silver@finnpartners.com<\/p>\n<p>\n        <strong>Investor Relations Contact:<\/strong>\n      <\/p>\n<p>Hans Vitzthum<br \/>LifeSci Advisors, LLC<br \/>(617) 430-7578<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=nfrOWJcagJMQ4uc2OjOoGCo5iSzoC0-Spcjc09JmFbvzxTCjJEOO_Ikm9RIqQ6NMGJfNkp7eIpQ2FKhZ-PGKzf1KePTC9NPdGrsnhU2jrmk=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Hans@LifeSciAdvisors.com<\/a><\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4ODk2MCM0MDYxMDQzIzIwMjgzMzk=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/b4360bdc-ed1a-455b-b91d-76d1aa40bd02\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEWARK, Calif., March 12, 2021 (GLOBE NEWSWIRE) &#8212; CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio webcast on Thursday, March 25, 2021 at 4:30 p.m. Eastern Time to discuss financial results for the fourth quarter and year ended December 31, 2020 and to provide a business update. Conference Call Details To access the live conference call, please dial 877-407-0784 from the U.S. and Canada, or 201-689-8560 internationally, Conference ID# 13715944. To access the live and subsequently archived webcast of the conference call, go to the Investors section of the company&#8217;s website at http:\/\/ir.cymabay.com\/events. &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cymabay-therapeutics-to-report-fourth-quarter-and-full-year-2020-financial-results-on-thursday-march-25-2021\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;CymaBay Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results on Thursday, March 25, 2021&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-456725","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>CymaBay Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results on Thursday, March 25, 2021 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cymabay-therapeutics-to-report-fourth-quarter-and-full-year-2020-financial-results-on-thursday-march-25-2021\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CymaBay Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results on Thursday, March 25, 2021 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEWARK, Calif., March 12, 2021 (GLOBE NEWSWIRE) &#8212; CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio webcast on Thursday, March 25, 2021 at 4:30 p.m. Eastern Time to discuss financial results for the fourth quarter and year ended December 31, 2020 and to provide a business update. Conference Call Details To access the live conference call, please dial 877-407-0784 from the U.S. and Canada, or 201-689-8560 internationally, Conference ID# 13715944. To access the live and subsequently archived webcast of the conference call, go to the Investors section of the company&#8217;s website at http:\/\/ir.cymabay.com\/events. &hellip; Continue reading &quot;CymaBay Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results on Thursday, March 25, 2021&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cymabay-therapeutics-to-report-fourth-quarter-and-full-year-2020-financial-results-on-thursday-march-25-2021\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-12T13:03:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4ODk2MCM0MDYxMDQzIzIwMjgzMzk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cymabay-therapeutics-to-report-fourth-quarter-and-full-year-2020-financial-results-on-thursday-march-25-2021\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cymabay-therapeutics-to-report-fourth-quarter-and-full-year-2020-financial-results-on-thursday-march-25-2021\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"CymaBay Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results on Thursday, March 25, 2021\",\"datePublished\":\"2021-03-12T13:03:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cymabay-therapeutics-to-report-fourth-quarter-and-full-year-2020-financial-results-on-thursday-march-25-2021\\\/\"},\"wordCount\":293,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cymabay-therapeutics-to-report-fourth-quarter-and-full-year-2020-financial-results-on-thursday-march-25-2021\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4ODk2MCM0MDYxMDQzIzIwMjgzMzk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cymabay-therapeutics-to-report-fourth-quarter-and-full-year-2020-financial-results-on-thursday-march-25-2021\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cymabay-therapeutics-to-report-fourth-quarter-and-full-year-2020-financial-results-on-thursday-march-25-2021\\\/\",\"name\":\"CymaBay Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results on Thursday, March 25, 2021 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cymabay-therapeutics-to-report-fourth-quarter-and-full-year-2020-financial-results-on-thursday-march-25-2021\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cymabay-therapeutics-to-report-fourth-quarter-and-full-year-2020-financial-results-on-thursday-march-25-2021\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4ODk2MCM0MDYxMDQzIzIwMjgzMzk=\",\"datePublished\":\"2021-03-12T13:03:29+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cymabay-therapeutics-to-report-fourth-quarter-and-full-year-2020-financial-results-on-thursday-march-25-2021\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cymabay-therapeutics-to-report-fourth-quarter-and-full-year-2020-financial-results-on-thursday-march-25-2021\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cymabay-therapeutics-to-report-fourth-quarter-and-full-year-2020-financial-results-on-thursday-march-25-2021\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4ODk2MCM0MDYxMDQzIzIwMjgzMzk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4ODk2MCM0MDYxMDQzIzIwMjgzMzk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cymabay-therapeutics-to-report-fourth-quarter-and-full-year-2020-financial-results-on-thursday-march-25-2021\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CymaBay Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results on Thursday, March 25, 2021\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CymaBay Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results on Thursday, March 25, 2021 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cymabay-therapeutics-to-report-fourth-quarter-and-full-year-2020-financial-results-on-thursday-march-25-2021\/","og_locale":"en_US","og_type":"article","og_title":"CymaBay Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results on Thursday, March 25, 2021 - Market Newsdesk","og_description":"NEWARK, Calif., March 12, 2021 (GLOBE NEWSWIRE) &#8212; CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio webcast on Thursday, March 25, 2021 at 4:30 p.m. Eastern Time to discuss financial results for the fourth quarter and year ended December 31, 2020 and to provide a business update. Conference Call Details To access the live conference call, please dial 877-407-0784 from the U.S. and Canada, or 201-689-8560 internationally, Conference ID# 13715944. To access the live and subsequently archived webcast of the conference call, go to the Investors section of the company&#8217;s website at http:\/\/ir.cymabay.com\/events. &hellip; Continue reading \"CymaBay Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results on Thursday, March 25, 2021\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cymabay-therapeutics-to-report-fourth-quarter-and-full-year-2020-financial-results-on-thursday-march-25-2021\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-12T13:03:29+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4ODk2MCM0MDYxMDQzIzIwMjgzMzk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cymabay-therapeutics-to-report-fourth-quarter-and-full-year-2020-financial-results-on-thursday-march-25-2021\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cymabay-therapeutics-to-report-fourth-quarter-and-full-year-2020-financial-results-on-thursday-march-25-2021\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"CymaBay Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results on Thursday, March 25, 2021","datePublished":"2021-03-12T13:03:29+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cymabay-therapeutics-to-report-fourth-quarter-and-full-year-2020-financial-results-on-thursday-march-25-2021\/"},"wordCount":293,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cymabay-therapeutics-to-report-fourth-quarter-and-full-year-2020-financial-results-on-thursday-march-25-2021\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4ODk2MCM0MDYxMDQzIzIwMjgzMzk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cymabay-therapeutics-to-report-fourth-quarter-and-full-year-2020-financial-results-on-thursday-march-25-2021\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cymabay-therapeutics-to-report-fourth-quarter-and-full-year-2020-financial-results-on-thursday-march-25-2021\/","name":"CymaBay Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results on Thursday, March 25, 2021 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cymabay-therapeutics-to-report-fourth-quarter-and-full-year-2020-financial-results-on-thursday-march-25-2021\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cymabay-therapeutics-to-report-fourth-quarter-and-full-year-2020-financial-results-on-thursday-march-25-2021\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4ODk2MCM0MDYxMDQzIzIwMjgzMzk=","datePublished":"2021-03-12T13:03:29+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cymabay-therapeutics-to-report-fourth-quarter-and-full-year-2020-financial-results-on-thursday-march-25-2021\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cymabay-therapeutics-to-report-fourth-quarter-and-full-year-2020-financial-results-on-thursday-march-25-2021\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cymabay-therapeutics-to-report-fourth-quarter-and-full-year-2020-financial-results-on-thursday-march-25-2021\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4ODk2MCM0MDYxMDQzIzIwMjgzMzk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4ODk2MCM0MDYxMDQzIzIwMjgzMzk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cymabay-therapeutics-to-report-fourth-quarter-and-full-year-2020-financial-results-on-thursday-march-25-2021\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"CymaBay Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results on Thursday, March 25, 2021"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/456725","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=456725"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/456725\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=456725"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=456725"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=456725"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}